Background-Mast cells are major effector cells in allergy and host defense responses. Their increased number and state of activation in perivascular tissue during atherosclerosis may point to a role in cardiovascular disorders. In the present study, we investigated the contribution of perivascular mast cells to atherogenesis and plaque stability in apolipoprotein E-deficient mice. Methods and Results-We show here that episodes of systemic mast cell activation during plaque progression in mice leads to robust plaque expansion. Targeted activation of perivascular mast cells in advanced plaques sharply increases the incidence of intraplaque hemorrhage, macrophage apoptosis, vascular leakage, and CXCR2/VLA-4 -mediated recruitment of leukocytes to the plaque. Importantly, treatment with the mast cell stabilizer cromolyn does prevent all the adverse phenomena elicited by mast cell activation. Conclusions-This is the first study to demonstrate that mast cells play a crucial role in plaque progression and destabilization in vivo. We propose that mast cell stabilization could be a new therapeutic approach to the prevention of acute coronary syndromes.
myocardial infarction, are commonly caused by erosion or rupture of vulnerable atherosclerotic plaques. [1] [2] [3] Inflammatory cells are considered to play a key role in the pathogenesis of plaque rupture. 4 -6 Indeed, one of the inflammatory cell types, the mast cell, [7] [8] has been shown to accumulate in the rupture-prone shoulder region of human atheromas. 9 Activated mast cells that contain proteases such as tryptase and chymase have been identified at the site of rupture in specimens of human coronary arteries. 10 -13 Human coronary artery specimens contain tumor necrosis factor-␣-rich activated mast cells, 14, 15 which potentially aggravate the ongoing inflammatory response and may ultimately lead to plaque destabilization. 16 
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Not only intimal inflammation but also inflammation of the arterial adventitia has been shown to influence the plaque vulnerability. 17 Activated mast cells have been identified in the adventitia of vulnerable and ruptured lesions in patients with myocardial infarction, 18 -20 and, more importantly, their number was found to correlate with the incidence of plaque rupture and erosion. 18 However, it remains to be clarified whether adventitial mast cells actively modulate lesion composition and are instrumental in causing plaque rupture or rather are part of the inflammatory cell recruitment secondary to plaque rupture.
In the present study, we demonstrate that systemic mast cell activation during atherogenesis leads to increased plaque progression. Moreover, we show that local activation of mast cells in the adventitia of advanced carotid artery plaques promotes macrophage apoptosis, microvascular leakage, and de novo leukocyte influx. Importantly, this culminates in a greatly enhanced incidence of intraplaque hemorrhage. Finally, mast cell stabilization by cromolyn was seen to prevent these pathophysiological events by inhibition of mast cell degranulation.
Methods
A detailed description of the Methods is given in the online-only Data Supplement.
Experimental Design
All animal work was performed in compliance with Dutch government guidelines. Male apolipoprotein E-deficient (ApoE -/-) mice, obtained from the local animal breeding facility, were fed a Westerntype diet that contained 0.25% cholesterol and 15% cacao butter (SDS, Sussex, UK). After 4 weeks of Western-type feeding, all isoflurane-anesthetized animals were skin-sensitized on days 1 and 2 with dinitrofluorobenzene (DNFB; 0.5% v/v, Janssen Chimica, Beerse, Belgium) or vehicle control solution (acetone:olive oil 4:1, nϭ7 per group) as described by Kraneveld et al. 21 On day 5, the mice were challenged intravenously by injection of dinitrophenyl-albumin (DNP; 1 mg/animal), which was repeated once weekly for another 2 weeks to induce systemic adventitial mast cell activation. A separate group of mice received an intraperitoneal injection of the mast cell stabilizer cromolyn (50 mg/kg; Sigma, Zwijndrecht, the Netherlands) 22,23 30 minutes before and after DNP challenge. After 8 weeks of diet feeding, the mice were anesthetized. In situ fixation through the left cardiac was performed 24 and brachiocephalic artery lesions were analyzed.
To determine the effect of local adventitial mast cell activation on advanced atherosclerotic lesions, carotid artery plaque formation was induced by perivascular collar placement in male ApoE -/mice as described previously. 24 Mice were anesthetized by subcutaneous injection of ketamine (60 mg/kg; Eurovet Animal Health, Bladel, the Netherlands), fentanyl citrate (1.26 mg/kg, Janssen Animal Health, Sauderton, UK), and fluanisone (2 mg/kg, Janssen Animal Health). Five weeks after collar placement all animals were skin-sensitized as described above (control: nϭ14; DNFB: nϭ13). On day 5, the mice were challenged perivascularly by application of pluronic F-127 gel (25% wt/vol) or pluronic F-127 gel that contained DNP (50 g/ animal) at the lesion site. To measure de novo infiltration of circulating leukocytes into the lesions, some of the mice were injected intravenously with rhodamine-6G (0.67 mg/kg) 25 to label circulating leukocytes. In a separate experimental set-up, 2 groups of mice (control: nϭ11; DNFB: nϭ10) received an intravenous injection that contained 25 mg/kg of cromolyn 30 minutes before local DNP or control challenge and twice daily during challenge by intraperitoneal injections with 50 mg/kg of cromolyn. Three days after challenge the animals were anesthetized and in situ perfusionfixation was performed, after which the carotid artery lesions were analyzed.
Lesion analysis, cell culture experiments, vascular leakage, and perfusion studies were performed as detailed in the online-only Data Supplement. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Statistical Analysis

Results
Systemic Mast Cell Activation and Plaque Morphometry
First, we delineated the effect of systemic mast cell activation during atherosclerotic lesion progression in ApoE -/mice. In the adventitia of the brachiocephalic artery lesions, the percentage of activated mast cells at 7 days after mast cell activation was 62Ϯ9% in controls, 75Ϯ7% in DNPchallenged mice, and 54Ϯ10% in DNP-challenged mice that were treated with the mast cell stabilizer cromolyn (PϭNS). Despite the fact that mast cells had only been activated 3 times during 8 weeks of lesion development, the brachiocephalic artery lesion size of DNP-challenged mice was significantly increased by Ͼ2-fold compared with controls (73Ϯ11ϫ10 3 m 2 versus 35Ϯ11ϫ10 3 m 2 ; PϽ0.05) ( Figure  1A and 1B). Interestingly, treatment of DNP-challenged animals with the mast cell stabilizer cromolyn prevented the DNP-induced plaque expansion (42Ϯ8ϫ10 3 m 2 ; PϽ0.05 compared with DNP-challenged mice). Relative macrophage content (monocyte and macrophage antibody, or MOMA-2, staining) did not differ between the groups (data not shown), and the amount of adventitial neutrophils was unchanged (20Ϯ1 in control mice, 19Ϯ5 in DNP-challenged mice, and 16Ϯ1 neutrophils/section in cromolyn-treated DNPchallenged mice; PϭNS).
Local Adventitial Mast Cell Activation and Plaque Morphology
Because mast cell density and activation is particularly high in the adventitia of human type V/VI atherosclerotic lesions, and as we cannot exclude a systemic inflammatory response when mast cells are activated as described above, we assessed the influence of focal and acute adventitial mast cell activation on advanced atherosclerotic plaques in ApoE -/mice. The hapten challenge was therefore applied perivascularly by administration of a DNP-loaded pluronic F-127 gel at the collar-induced carotid artery lesion. 24 Morphometric analysis of the lesions did not reveal any differences in plaque size between control and DNPchallenged animals at 3 days after challenge (54Ϯ8ϫ10 3 m 2 versus 59Ϯ9ϫ10 3 m 2 , respectively) ( Figure 2A ), which was also not affected by cromolyn treatment during challenge of the animals (control: 54Ϯ7ϫ10 3 m 2 versus DNPchallenged: 66Ϯ11ϫ10 3 m 2 ). Medial surface area was slightly increased in the DNP-challenged mice (42Ϯ4ϫ10 3 m 2 versus 34Ϯ2ϫ*10 3 m 2 in controls; Pϭ0.04), which did not occur after cromolyn treatment (DNP-challenged: 36Ϯ3ϫ10 3 m 2 versus controls: 35Ϯ3ϫ10 3 m 2 ).
Resting and activated mast cells in the adventitia of the lesions were detected by toluidin blue ( Figure 2B ). Alcian blue/saphranin O staining revealed that the majority of the adventitial mast cells were connective tissue-type mast cells (98.6%). 26 Both the number of adventitial mast cells in DNP-challenged mice (7.5Ϯ1.4 versus 4.8Ϯ0.7 MC/mm 2 adventitial tissue in the control mice; PϽ0.05) ( Figure 2C ) and the percentage of degranulated adventitial mast cells were significantly increased (74.7Ϯ3.9% versus 44.6Ϯ5.7% in control animals; PϽ0.001) ( Figure 2D ) at 3 days after perivascular challenge. Cromolyn treatment completely abolished the DNP-induced mast cell recruitment (3.1Ϯ0.5 MC/ mm 2 adventitial tissue, PϽ0.01, compared with DNPchallenged mice that had not received cromolyn) ( Figure 2C ), and the amount of activated mast cells returned to basal levels (32.4Ϯ4.9% in controls and 30.4Ϯ7.4% in DNP mice that received cromolyn) ( Figure 2D ). In the adventitia of these lesions, the total number of neutrophils did not differ between any of the groups (Figure 2E , PϭNS), which indicated that cromolyn did not affect neutrophil infiltration.
Strikingly, further analysis of the plaque morphology revealed massive intraplaque hemorrhages, characterized by the presence of intimal erythrocytes, in 7 of 26 plaques of DNP-challenged animals ( Figures 3A and 3F ), whereas we observed no such phenomena in controls ( Figure 3B ) (0 of 27, Pϭ0.004). CD31positive microvessels were detected, generally in close proximity of hemorrhages ( Figure 3C ). A Perl's iron staining confirmed these findings (6 of 26 compared with 0 of 27 for control mice; Pϭ0.01) ( Figure 3D , 3E, and 3F). Iron staining was found to correlate with the presence of intraplaque hemorrhage (PϽ0.0001), colocalized with ceroid-rich regions (data not shown) and was confined mostly to the central atheroma. Of 6 iron-positive lesions, 5 arteries revealed iron staining also in the media (Pϭ0.02) and enhanced medial thickening. Importantly, none of the cromolyn-treated DNP-challenged mice showed intraplaque hemorrhage or iron staining (Pϭ0.01 compared with DNP-challenged animals that had not received cromolyn) ( and control and DNP-challenged animals that also received the mast cell stabilizer cromolyn (white bars). B, Toluidin Blue staining of a resting (left) and an activated (degranulating, right) mast cell (indicated by arrows) in the adventitia of an atherosclerotic lesion (1000ϫ). C, Total adventitial mast cell content in control and DNP-treated animals (black bars) and cromolyn-treated control and DNP-challenged mice (white bars). D, Adventitial mast cell degranulation in control and DNP-challenged mice, which was found to be significantly increased in the latter group. Cromolyn treatment normalized the levels of mast cell activation in the DNPchallenged animals. E, Adventitial neutrophil levels did not differ between the groups and were not affected by cromolyn treatment.
In Vivo Apoptosis
As mast cell degranulation was reported to promote apoptosis of vascular smooth muscle cells and endothelial cells, 13, 27, 28 we stained sections for apoptotic cells by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining ( Figure 4A ). Indeed, we observed a significant increase in TUNEL-positive area in DNP-challenged lesions (3.3Ϯ0.5% TUNEL-stained area compared with 0.6Ϯ0.2% in control animals; Pϭ0.002). Although the iron-negative lesions of the DNP-challenged animals displayed enhanced levels of TUNEL-positive area (2.6Ϯ0.6% TUNEL-positive area; Pϭ0.02 compared with controls), the degree of apoptosis was even more pronounced in the iron-positive sections (4.8Ϯ0.6% TUNEL-positive area; Pϭ0.01) ( Figure 4B ). These data were confirmed by scoring of the TUNEL-positive nuclei in the plaque (6.1Ϯ2.0% versus 2.1Ϯ0.6% in the controls; Pϭ0.04) (Figure 4C) . The majority of the apoptotic cells were located in the central atheroma rather than in the SMC-rich lesion cap (Pϭ0.04) ( Figure 4C ), which suggests that adventitial mast cell degranulation preferentially induces macrophage apoptosis. Strikingly, no differences were observed between controls and DNP-challenged mice that had been treated with cromolyn (1.5Ϯ0.7% versus 2.4Ϯ0.9% TUNEL-stained area, respectively; Pϭ0.4), which suggests that cromolyn prevented the adventitial mast cell induced macrophage apoptosis.
Mast Cell Releasate Induces Macrophage Apoptosis
Releasates of MC/9 cells and of mast cell freshly isolated from the peritoneal cavity (peritoneal mast cells) were analyzed after stimulation with compound 48/80 for their composition. MC/9 releasate was previously shown to contain histamine 29 and was demonstrated to have ␤-hexosaminidase activity (1.3% of total release) as well as to contain tryptase (1.2% of total release). Peritoneal mast cells releasate also showed ␤-hexosaminidase activity (16% of total release) and contained chymase, tryptase, vascular endothelial growth factor, and histamine (7.8%, 3.5%, 18.7%, and 5.5% of total release, respectively).
Supernatant from MC/9 mast cells induced apoptosis of RAW 264.7 macrophages by up to 5-fold (21.8Ϯ0.7% of apoptotic cells versus 4.4Ϯ0.3% for control medium) ( Figure  5A ). To pinpoint the culprit mast cell constituent, we assessed the effect of tryptase (leupeptin), chymase (soy bean trypsin inhibitor) as well as of histamine receptor antagonists in mast cell-induced apoptosis. Soy bean trypsin inhibitor, leupeptin, and the H 1 -receptor antagonist triprolidine were able to inhibit mast cell-induced macrophage apoptosis, whereas the H 2 -and H 3 -receptor antagonists cimetidine and thioperamide were ineffective ( Figure 5A ). None of the inhibitors affected endogenous apoptosis or H 2 O 2 -induced apoptosis of RAW 264.7 cells, which thus excluded that the inhibitors used are pro-or antiapoptotic by themselves (data not shown). As both the protease inhibitors and the H 1 -receptor antagonist completely inhibited macrophage apoptosis, we verified whether histamine acts synergistically on tryptase-induced apoptosis or vice versa. Incubation with histamine for 16 hours strongly increased macrophage apoptosis (9-fold; PϽ0.01), whereas subsequent posttreatment with tryptase (6 hours) led to an additive (1.8-fold) increase in macrophage apoptosis compared with treatment with histamine only. Tryptase treatment for 6 hours appeared to be ineffective. Conversely, priming of macrophages with tryptase for 16 hours slightly enhanced RAW 264.7 cell apoptosis (13Ϯ3% compared with 4Ϯ2% for untreated cells; PϽ0.05), but did not sensitize macrophages , which demonstrated intraplaque hemorrhages only in the first lesion (100ϫ). In A, a high-power magnification of an intraplaque hemorrhage shows erythrocytes extravasated in the intima of a DNP-challenged mouse (400ϫ). C, CD31 staining of a microvessel present in a DNP-challenged lesion (1000ϫ). Perl's iron staining of a DNP-(D) and a vehicle control-challenged artery (E), which revealed large areas with iron deposits only in the DNP-challenged plaque (100ϫ). F, Quantification of the number of plaques that contained intraplaque hemorrhages and iron deposits in vehicle and DNP-challenged mice, which established a strongly increased frequency of hemorrhages after DNP challenge (Pϭ0.004), an increase that was confirmed by Perl's iron staining (Pϭ0.01). Cromolyn treatment prevented the increase in intraplaque hemorrhage and iron deposits in DNP-challenged animals (Pϭ0.01 compared with DNP-challenged mice).
for histamine-induced apoptosis (data not shown). In analogy to the MC/9 experiments, the supernatant of peritoneal mast cells and that of primary cultured bone marrow-derived mast cells, both degranulated with compound 48/80, induced peritoneal macrophage apoptosis ( Figure 5B ). In agreement with previous studies, 12, 13 supernatant of degranulated MC/9 cells induced vascular smooth muscle cell apoptosis after 48 hours (data not shown), although vascular smooth muscle cells appeared to be less susceptible to mast cell-induced apoptosis than macrophages. Furthermore, we determined whether mast cell supernatant from MC/9 cells, peritoneal mast cells, and bone marrowderived mast cells, degranulated with compound 48/80, was able to induce endothelial cell proliferation. Indeed, murine endothelial H5V cells showed an increase in proliferation up to 200% when exposed to supernatant of either the activated mast cell line or the primary cultured mast cells (PϽ0.05) ( Figure 5C ).
Cromolyn Effects on Leukocytes
To determine whether cromolyn was mast cell specific, we systemically challenged C57Bl6 mice and analyzed effects of cromolyn on peritoneal cell composition. Cromolyn treatment did not affect relative neutrophil ( Figure 6A ), monocyte ( Figure 6B ), or T-cell content ( Figure 6C ). However, the number of peritoneal CD117 ϩ mast cells was significantly reduced by treatment with cromolyn (PϽ0.001) ( Figure 6D ). Similar results were obtained after cromolyn treatment of locally challenged C57Bl6 mice (online-only Data Supplement Figure I ). In line with these data, after perivascular DNP challenge of mast cell-deficient Kit(W -sh /W -sh ) mice, 30 cromolyn did not affect neutrophil and monocyte levels in the peritoneal cavity (online-only Data Supplement Figure II) . Myeloperoxidase activity of peritoneal neutrophils also remained unaltered by cromolyn treatment after systemic (Figure 6E ) and local challenge ( Figure 6F) in C57Bl6 mice and did not differ in cromolyn-treated Kit(W -sh /W -sh ) mice after perivascular challenge ( Figure 6G) .
Analysis of DNFB-sensitized skin segments of C57Bl6 mice revealed that cromolyn treatment did not affect the percentage of neutrophils and eosinophils. The percentage of mast cells was significantly enhanced in these mice after DNP challenge (PϽ0.01), an effect that was reduced by cromolyn administration (online-only Data Supplement Figure IIIA) . In Kit(W -sh /W -sh ) mice, cromolyn did not alter the levels of skin neutrophils and eosinophils after DNFB sensitization, whereas mast cells were, as expected, undetectable in these mice (online-only Data Supplement Figure IIIB) .
After systemic challenge in C57Bl6 mice, serum levels of IL-2, IFN␥, IL-4, and tumor necrosis factor-␣ were not significantly different between control and DNP-challenged animals, although a trend toward reduced IL-4 levels was observed (Pϭ0.07 compared with control mice) (online-only Data Supplement Figure IV) . As mentioned previously, we cannot exclude the possibility that systemic inflammatory responses after systemic mast cell activation may indirectly have influenced atherogenesis. Therefore, we next focused on mast cell activation locally at the lesion site. As anticipated, after local challenge serum IFN␥ remained undetectable, whereas serum IL-2, IL-4, and tumor necrosis factor-␣ did not differ between the groups (online-only Data Supplement Figure V) . Similar results were obtained in Kit(W -sh /W -sh ) mice (online-only Data Supplement Figure VI ).
Microvascular Leakage In Vivo
Apart from promoting macrophage apoptosis, mast cells have been thought to induce vascular leakage. 31, 32 We indeed observed that after intradermal injection of 5ϫ10 5 activated MC/9 cells in mice, vascular leakage as judged by Evans Blue spot size was significantly enhanced compared with PBS and was demonstrated to only be inhibited by the H 1 -receptor antagonist triprolidine (online-only Data Supplement Figure  VII, PϽ0.001 ). More importantly, carotid artery lesions, perivascularly challenged with DNP and injected with Rhodamine 6G to label circulating leukocytes, contained a higher number of Rhodamine-positive cells than controls (Pϭ0.0002) ( Figure 7A ) at 3 days after challenge. Whereas in control mice the sparse Rhodamine-positive leukocytes were mainly found at the plaque surface, in the DNP-challenged mice a considerable portion of the Rhodamine-positive cells was detected in the central atheroma near the elastic lamina, which suggests that the latter had in part migrated through microvessels inside the plaque that were rendered permeable by mast cells.
In Vivo Intravital Microscopy/Ex Vivo Perfusion
To establish whether adventitial mast cell activation affects the adhesion of leukocytes to atherosclerotic plaques from the luminal side, circulating leukocytes were Rhodamine-6Glabeled in vivo and adhesion of these cells to DNP-and control-challenged atherosclerotic lesion was monitored by intravital microscopy. The adhesion of labeled leukocytes to plaques was 2.5-fold increased after perivascular mast cell activation (49Ϯ6 versus 19Ϯ4 leukocytes/microscopic field for DNP versus vehicle control plaques, respectively;
Pϭ0.0009) ( Figure 7B) . Ex vivo perfusion studies on the adhesion of Calcein-labeled monocytic MonoMac-6 cells confirmed these findings (25Ϯ6 cells/field in DNPchallenged arteries versus 9Ϯ2 cell/field in control arteries; Pϭ0.02) ( Figure 7B ). Strikingly, antibody blockade of either the KC receptor CXCR2 or the ␤1-integrin and vascular cell adhesion molecule-1 receptor VLA-4 on the MonoMac-6 cells completely inhibited the mast cell-mediated monocyte adhesion to the atherosclerotic plaque, whereas blockade of CCR1, CCR3, and CCR5 with Met-RANTES and isotype control antibodies had no effect. None of the treatment modalities significantly reduced monocytic cell adhesion to control atherosclerotic plaques in the area of interest.
Discussion
Activated mast cells have been shown to accumulate in the arterial adventitia during plaque progression and are abundantly present in the adventitia of vulnerable and ruptured lesions. To date, it remains to be clarified whether these adventitial mast cells contribute to plaque progression and whether these cells are instrumental in plaque rupture. To address these key questions, we recruited and activated mast cells in the adventitia of atherosclerotic lesions in ApoE -/mice. We demonstrate that systemic mast cell activation during atherogenesis leads to increased plaque progression and that focal activation of mast cells in the adventitia of advanced plaques increases the incidence of intraplaque hemorrhage. Inhibition of mast cell degranulation by the mast cell stabilizer cromolyn prevented these pathophysiological events.
Systemic mast cell activation was seen to aggravate spontaneous plaque progression in the brachiocephalic artery of ApoE -/mice, an effect that was not observed after prior mast cell stabilization with cromolyn. More importantly, as most mast cells are present in type V/VI human atherosclerotic lesions, we have addressed the effect of focal mast cell activation on preexisting collar-induced carotid artery plaques, which are more easily accessible for local intervention. These atherosclerotic plaques, formed proximal to the collar, were previously shown to be shear stress-induced and absolutely lipid-dependent, thus representing a valid model of true atherosclerosis. 24, 33 The DNP challenge led to a striking and acute increase in the incidence of intraplaque hemorrhage within 3 days after challenge. Also, iron deposits were observed in the media of these lesions, which suggests that culprit factors likely entered the intima after adventitial release and crossing of the media. Lesions with intraplaque hemorrhage tended to contain relatively more adventitial mast cells than those lacking hemorrhages, a finding that is in line with the observation by Laine et al 18 that the adventitia of ruptured lesions in human coronary artery species contained increased levels of mast cells. Importantly, the total number of mast cells detected in the adventitia of mouse carotid artery plaques corresponded with that observed in adventitial tissue of human plaques, 18, 19 which indicated that the mouse model offers a realistic representation of the human situation. Intraplaque hemorrhage seemed to colocalize with ceroid-rich regions in close proximity to microvessels. Interestingly, Kolodgie et al 34 reported that intraplaque hemorrhage is a potent proatherogenic stimulus and risk factor in plaque destabilization, as it is accompanied by deposition of erythrocyte-associated cholesterol and by enlargement of the necrotic core of the atherosclerotic plaque. This concurs with findings of Kockx et al, 35 that phagocytosis of accumulated erythrocytes by activated macrophages leads to ceroid production and further plaque expansion, which may promote the formation of rupture-prone lesions. Treatment of mice with cromolyn during DNP challenge normalized the extent of mast cell degranulation in the adventitia and prevented intraplaque hemorrhage. Importantly, cromolyn treatment was demonstrated to be mast cell-specific at the dosage used in our animal models and did not exhibit any side effects on other cell types such as neutrophils and macrophages. These data imply that inhibition of perivascular mast cell degranulation may help to maintain plaque stability.
Mast cells were reported to induce apoptosis of cardiomyocytes, 36 vascular smooth muscle cells, 12, 13, 27 and endothelial cells 28 in vitro, which could translate to reduced plaque stability. 37, 38 Indeed, we observed a highly significant increase of intimal apoptotic nuclei in the DNP-challenged mice. To our surprise, apoptosis was mainly localized in the central atheroma, which implied that the majority of apoptotic cells are of macrophage rather than of vascular smooth muscle cell origin. To date, mast cell degranulation has not been linked to macrophage apoptosis. Macrophage apoptosis may very well result in an enlarged necrotic core of the lesions and in the release of tissue factor-rich apoptotic microbodies, 39 which thereby decrease plaque stability and promote thrombosis. Our in vitro findings concurred with the in vivo data, in that macrophages displayed a high susceptibility to mast cell-induced apoptosis, whereas vascular smooth muscle cells appeared to be less sensitive. Protease inhibitors were able to prevent the mast cell-induced macrophage apoptosis, and an H 1 -receptor antagonist could completely blunt macrophage apoptosis. Both tryptase and chymase were suggested to be proapoptotic by themselves 12, 13, 27 but also to potentiate the proapoptotic action of histamine, 40 a hypothesis that was confirmed by our in vitro data.
DNP challenge substantially increased intimal influx of erythrocytes. We demonstrate here that mast cell degranulation enhances microvascular leakage ( Figure 7C ). Circulating leukocytes were seen to extravasate possibly through microvessels rendered permeable by mast cells in response to mast cell-derived chemotactic stimuli, as judged by the increased presence of rhodamine-labeled leukocytes in the DNP-treated plaque. In vitro studies showed endothelial proliferation in response to mitogenic factors, possibly vascular endothelial growth factor secreted by mast cells, 41 which could result in enhanced outgrowth of microvessels and transform the lesion into even more leakage-prone plaques. In neovascularized areas of human coronary atheromas, it was demonstrated that mast cells colocalized with intraplaque microvessels. 42 Furthermore, mast cells that contained basic fibroblast growth factor, a potent angiogenic factor, were located near microvessels in the intima and adventitia of human coronary artery lesions, 43 a finding that suggests that mast cells might indeed play a role in neoangiogenesis, vascular leakage, and plaque progression.
Furthermore, we demonstrated that perivascular mast cell activation increased leukocyte and in particular monocyte adhesion to the proximal area of atherosclerotic plaques in a CXCR2-and vascular cell adhesion molecule-1-dependent manner. Murine mast cells have previously been shown to release the CXCR2 ligand KC 44 (or its human ortholog interleukin-8), 45, 46 suggesting that the arrest-triggering response directly originates from activated mast cells. This is also conceivable, as tissue-derived chemokines, such as interleukin-8, can be abluminally internalized and transcytosed to the luminal side of endothelial cells, where the chemokines can exert their effects. 47 Previous studies in ex vivo perfused arteries have revealed that monocyte arrest on early atherosclerotic endothelium is also mediated by VLA-4 and triggered by KC via CXCR2. 48 In conjunction with our results, this finding indicates interesting mechanistic parallels in the contribution of these molecules to atherogenic recruit-ment at different stages (eg, between initial arrest and into advanced plaques destabilized by mast cells).
In conclusion, we are the first to provide in vivo proof that mast cells contribute significantly to atherosclerotic plaque progression. Moreover, we show that perivascular mast cells can promote macrophage apoptosis, increase leukocyte influx, and enhance microvascular leakage in preexisting atherosclerotic plaques, effects that result in a sharply increased risk of intraplaque hemorrhage and plaque destabilization. Thus, our present in vivo findings concur with previous in vitro findings 16 and point to a significant role for activated mast cells in plaque stability and acute coronary syndromes. We propose that mast cell stabilization can be an effective new therapeutic approach in the prevention of acute coronary syndromes.
